Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for CLVSF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CLVSF and 80,000+ other tickers.
See exactly how CLVSF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CLVSF and 80,000+ other tickers.
CellaVision AB (publ), a company established in Lund, Sweden, in 1994, specializes in the development and distribution of digital analytical solutions for blood and body fluid samples. Their offerings cater to the healthcare services sector, with a significant global presence spanning Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific region. The company's product portfolio includes advanced hardware such as the CellaVision DM1200 and CellaVision DM9600, which are designed to automatically capture digital images from blood smears and various body fluid preparations…
CellaVision AB (publ) (CLVSF) Q2 2026 Earnings Call Transcript
CellaVision AB (publ) (CLVSF) Q4 2025 Earnings Call Transcript
CellaVision AB (publ) (OTCPK:CLVSF) Q3 2025 Earnings Call November 6, 2025 5:00 AM EST Company Participants Simon Østergaard - CEO & President Conference Call Participants Simon Larsson Ulrik Trattner Christian Lee - Pareto Securities AS, Research Division Ludvig Lundgren - Nordea Markets, Research Division Presentation Operator Welcome to CellaVision Q3 Report 2025. [Operator Instructions] Now I will hand the conference over to CEO, Simon Ostergaard.